Fu­sion Phar­ma marks in-house ra­dio­phar­ma man­u­fac­tur­ing suc­cess, de­tails PhII/III tri­al study

Fu­sion Phar­ma­ceu­ti­cals said it has man­u­fac­tured the first clin­i­cal dose of its ra­dio­phar­ma­ceu­ti­cal as­set in-house and has agreed with the FDA on the de­sign of a Phase II/III study in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer.

The Cana­di­an com­pa­ny has se­cured good man­u­fac­tur­ing prac­tice (GMP) val­i­da­tion for its man­u­fac­tur­ing fa­cil­i­ty in Hamil­ton, On­tario, lead­ing to the pro­duc­tion of its tar­get­ed al­pha ther­a­py, a Thurs­day re­lease states. Tar­get­ed al­pha ther­a­py, or TAT, is an ap­proach where­by the ra­dio­ther­a­py goes through al­pha de­cay, which can be cy­to­tox­ic to near­by cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER